Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon3.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ARHGEF1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The p115-RhoGEF also known as ARHGEF1 is a guanine nucleotide exchange factor that primarily activates RhoA a small GTPase. It has a molecular mass of approximately 115 kDa. You find p115-RhoGEF predominantly expressed in the heart lung and brain tissues. This protein facilitates the exchange of GDP for GTP on RhoA triggering downstream signaling events essential for cellular functions like growth motility and organization of cytoskeletal structures.
Biological function summary
P115-RhoGEF plays an important role in regulating actin cytoskeleton dynamics and transmitting signals from G-protein-coupled receptors. The protein is part of a signaling complex that includes heterotrimeric G proteins. Through its influence on the actin cytoskeleton p115-RhoGEF helps control changes in cell shape and movement. These activities contribute significantly to various cellular processes including differentiation and migration.
Pathways
P115-RhoGEF is an essential component in the RhoA signaling pathway. This pathway regulates cytoskeletal dynamics and has critical implications for processes like cell adhesion and migration. p115-RhoGEF collaborates with other proteins such as Gα12/13 subunits to mediate its signaling effects. Besides the RhoA pathway p115-RhoGEF also interacts with the PI3K/Akt pathway influencing cellular survival and apoptosis.
Disruptions in p115-RhoGEF activity link to cardiovascular diseases and certain forms of cancer. Alterations in its function may lead to improper cell movement contributing to metastasis in cancer development. Additionally abnormal regulation of RhoA signaling connected to p115-RhoGEF could compromise vascular integrity implicating this protein in hypertension. During disease progression p115-RhoGEF interacts with other proteins like ROCK1 to exert these pathological effects.
